EAM
ARRY

EverPoint Asset Management’s Array Biopharma Inc ARRY Stock Holding History

EverPoint Asset Management’s Portfolio ARRY Stock Details ARRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$22M Buy
+2,500,000
New +$18.4M 0.41% 57

Other funds holding ARRY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return

EverPoint Asset Management's ARRY Position: Q4 2016 in Review

EverPoint Asset Management opened a new position in Array Biopharma Inc (ARRY) in Q4 2016: 2,500,000 shares worth $22M. The stake represents 0.41% of the portfolio and ranks #57 among its holdings.

167 funds tracked by Wall St. Rank hold ARRY as of Q4 2016.

  • EverPoint Asset Management held 2,500,000 shares of Array Biopharma Inc worth $22M as of Q4 2016.
  • Array Biopharma Inc was a new EverPoint Asset Management position in Q4 2016.
  • Array Biopharma Inc made up 0.41% of EverPoint Asset Management's portfolio in Q4 2016, its #57 holding.
  • 167 funds tracked by Wall St. Rank held Array Biopharma Inc as of Q4 2016.

Based on EverPoint Asset Management's 13F filing for Q4 2016, filed 14 Feb 2017.